1. Charlton MR. Protein metabolism and liver disease. Baillieres Clin Endocrinol Metab 1996; 10: 617-635.
2. Kawaguchi T, Yamagishi S, Sata M. Branched-chain amino acids and pigment epithelium-derived factor: novel therapeutic agents for hepatitis c virus-associated insulin resistance. Curr Med Chem 2009; 16: 4843-4857.
3. Lautz HU, Selberg O, Korber J, et al. Forms of malnutrition in patients with liver cirrhosis. Clin Invest 1992; 70:178–86.
4. Crawford DHG, Shepherd RW, Halliday JW, et al. Body composition in nonalcoholic cirrhosis: the effect of disease etiology and severity on nutritional compartments. Gastroenterology 1994; 106:1611–7.
5. Kondrup J, Muller MJ. Energy and protein requirements of patients with chronic liver disease. J Hepatol 1997; 27: 239–47.
6. Alberino F, Gatta A, Amodio P, et al. Nutrition and survival in patients with liver cirrhosis. Nutrition 2001; 17: 445–50.
7. Tajika M, Kato M, Mohri H, et al. Prognostic value of energy metabolism in patients with viral liver cirrhosis. Nutrition 2002; 18: 229–34.
8. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophagealvarices. Br J Surg 1973; 60:646 – 649.
9. Christensen E, Schlichting P, Fauerholdt L, et al. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology 1984; 4:430–435.
10. Merkel C, Bolognesi M, Finucci GF, et al. Indocyanine green intrinsic hepatic clearance as a prognostic index of survival in patients with cirrhosis. J Hepatol 1989; 9: 16–22.
11. Cabre E, Gonzalez-Huix F, Abad-LaCruz A, et al. Effects of total enteral nutrition on short-term outcome of severely malnourished cirrhosis. Gastroenterology 1990; 98: 715–720.
12. Mendenhall CL, Tosch T, Weesner RE, et al. VA cooperative study on alcoholic hepatitis II: prognostic significance of protein-calorie malnutrition. Am J Clin Nutr 1986;43:213
13. Christie ML, Sack DM, Pomposelli J et al. Enriched branched-chain amino acid formula versus a casein-based supplement in the treatment of cirrhosis. JPEN J Parenter Enteral Nutr 1985; 9: 671–8.
14. McGhee A, Henderson JM, Millikan WJ Jr et al. Comparison of the effects of Hepatic-Aid and a Casein modular diet on encephalopathy, plasma amino acids, and nitrogen balance in cirrhotic patients. Ann Surg1983; 197:288– 93.
15. Italian Multicentre Cooperative Project on Nutrition in Liver Cirrhosis. Nutritional status in cirrhosis. J Hepatol 1994; 21: 317–25.
16. Marchesini G, Bianchi G, Merli M, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double- blind, randomized trial. Gastroenterology 2003; 124 (7):1792–1801.
17. Muto Y, Yoshida T. Effect of oral supplementation with branched- chain amino acid granules on improvement of protein nutrition in decompensated liver cirrhosis: a cross-over controlled study. In: Ogoshi S, Okada A, eds. Parenteral and enteral hyper-alimentation. Amsterdam: Excerpta Medica, 1984:280–292.
18. Muto Y, Yoshida T, Sato S, et al. Effect of oral supplementation with BCAAS-G on the prognosis of liver cirrhosis. JJPEN 1992; 14: 765–775.
19. Kawaguchi T, Izumi N, Charlton MR, Sata M. Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology. 2011; 54(3):1063-1070.
20. Charlton M. Branched-chain amino acid enriched supplements as therapy for liver disease. J Nutr. 2006; 136(suppl 1):295S-298S.
21. Plauth M, Schutz T. Branched-chain amino acids in liver disease: new aspects of long known phenomena. Curr Opin Clin Nutr Metab Care. 2011; 14(1):61-66.
22. Yoshizawa F. New therapeutic strategy for amino acid medicine: nota- ble functions of branched chain amino acids as biological regulators. J Pharmacol Sci. 2012; 118(2):149-155.
23. Paul HS, Adibi SA. Activation of hepatic branched chain alpha- keto acid dehydrogenase by a skeletal muscle factor. J Biol Chem. 1982; 257(21):12581-12588.
24. Damuni Z, Merryfield ML, Humphreys JS, Reed LJ. Purification and properties of branched-chain alpha-keto acid dehydrogenase phosphatase from bovine kidney. Proc Natl Acad Sci U S A. 1984; 81(14):4335- 4338.
25. Holecek M. Three targets of branched-chain amino acid supplementation in the treatment of liver disease. Nutrition. 2010; 26(5):482-490.
26. Marchesini G, Dioguardi FS, Bianchi GP, et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy: a randomized double-blind casein-controlled trial. J Hepatol 1990; 11: 92–101.
27. Kato M, Miwa Y, Tajika M, et al. Preferential use of branched-chain amino acids as an energy substrate in patients with liver cirrhosis. Intern Med 1998; 37:429–34.
28. Schuppan, D., and Afdhal, N. H. (2008). Liver cirrhosis. The Lancet, 371(9615), 838–851. doi: 10.1016/s0140-6736(08) 60383-9
29. Schaffner H, Popper H. Capillarization of the sinusoids. Gastroenterology. 1963; 44: 339–42.
30. Fischer JE, Funovics JM, Aguirre A, James JH, Keane JM, Wesdorp RI, et al. The role of plasma amino acids in hepatic encephalopathy. Surgery. 1975; 78:276–90.
31. Dasarathy S, Hatzoglou M. Hyperammonemia and proteostasis in cirrhosis. Curr Opin Clin Nutr Metab Care. 2018; 21:30–6.
32. Fischer JE, Baldessarini RJ. False neurotransmitters and hepatic failure. Lancet 1971; ii: 75–80.
33. Fischer JE, Rosen HM, Ebeid AM, et al. The effect of normalization of plasma amino acids on hepatic encephalopathy in man. Surgery 1976; 80: 77–91.
34. A.S.P.E.N. Board of Directors. The clinical guidelines task force: guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients, Liver disease. J Parenter Enter Nutr 2002; 26: 65SA–8SA.
35. Hayashi M, Ohnishi H, Kawada Y, et al. Augmented utilization of branched-chain amino acids by skeletal muscle in decompensated liver cirrhosis in special relation to ammonia detoxication. Gastroenterol Jpn 1981; 16:64–70.
36. Yamato M, Muto Y, Yoshida T, et al. Clearance rate of plasma branched-chain amino acids correlates significantly with blood ammonia level in patients with liver cirrhosis. Hepatol Res 1995; 3: 91–6.
37. Leweling H, Breitkreutz R, Behne F, et al. Hyperammonemia- induced depletion of glutamate and branched-chain amino acids in muscle and plasma. J Hepatol 1996; 25: 756–62.
38. Munro HN, Fernstrom JD, Wurtman RJ. Insulin, plasma amino acid imbalance and hepatic coma. Lancet 1975; I: 724–72.
39. Kato A. Abnormality in plasma branched chain amino acid in chronic hepatic failure: on its relationship with ammonia and insulin. J Iwate Med Assoc 1984; 36: 565–76 (in Japanese).
40. Rabbani P, Prasad AS. Plasma ammonia and liver ornithine trans-carbamoylase activity in zinc-deficient rats. Am J Physiol. 1978; 235(2):E203 -E206.
41. Moriyama M, Matsumura H, Fukushima A, et al. Clinical significance of evaluation of serum zinc concentrations in C-viral chronic liver disease. Dig Dis Sci. 2006; 51(11):1967-1977.
42. Nagasue N, Kolno H, Chang YC, Nakamura T. Iron, copper and zinc level in serum and cirrhotic liver of patients with and without hepatocellular carcinoma. Oncology. 1989; 46 (5):293-296.
43. Riggio O, Merli M, Capocaccia L, et al. Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis. Hepatology. 1992; 16(3):785-789.
44. Aquilio E, Spagnoli R, Riggio D, Seri S. Effects of zinc on hepatic orni- thinetranscarbamylase (OTC) activity. J Trace Elem Electrolytes Health Dis. 1993; 7(4):240-241.
45. Hayashi M, Ikezawa K, Ono A, et al. Evaluation of the effects of combination therapy with branched-chain amino acid and zinc supplements on nitrogen metabolism in liver cirrhosis. Hepatol Res. 2007; 37(8):615-619.
46. Takuma Y, Nouso K, Makino Y, Hayashi M, Takahashi H. Clinical trial: oral zinc in hepatic encephalopathy. Aliment Pharmacol Ther. 2010; 32(9):1080-1090.
47. Ndraha S, Hasan I, Simadibrata M. The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition. Acta Med Indones. 2011; 43(1):18-22.
48. Malaguarnera M, Risino C, Cammalleri L, et al. Branched chain amino acids supplemented with L-acetylcarnitine versus BCAAS treatment in hepatic coma: a randomized and controlled double blind study. Eur J Gastroenterol Hepatol. 2009; 21(7):762-770.
49. Moriwaki H, Miwa Y, Tajika M, et al. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem Bio- phys Res Commun 2004; 313:405–409.
50. Yoshida T, Muto Y, Moriwaki H, et al. Effect of long-term oral supplementation with branched-chain amino acid granules on the prognosis of liver cirrhosis. J Gastroenterol 1989; 24:692–698.
51. Selberg O, Bottcher J, Tusch G, et al. Identification of high- or low-risk patients before liver transplantation: a prospective cohort study of nutritional and metabolic parameters in 150 patients. Hepatology 1997; 25:652–657.
52. ASPEN Board of Directors and The Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients: liver disease. JPEN 2002; 26:65SA–68SA.
53. Hara K, Yonezawa K, Weng QP, et al. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 1998; 273:14484 –14494.
54. Proud CG. Regulation of mammalian translation factors by nutrients. Eur J Biochem 2002; 269: 5338 –5349.
55. Bianchi GP, Marchesini G, Zoli M, et al. Oral BCAAS supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels. Hepatogastroenterology. 1992; 39(5):443-446.
56. Horst D, Grace ND, Conn HO, et al. Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial. Hepatology. 1984;4(2):279-287.
57. Dhiman RK, Saraswat VA, Sharma BK, et al. Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver. J Gastroenterol Hepatol. 2010;25(6):1029-1041.
58. Bajaj JS, Cordoba J, Mullen KD, et al. Review article: the design of clinical trials in hepatic encephalopathy—an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther. 2011; 33(7):739-747.
59. Kato A, Tanaka H, Kawaguchi T, et al. Nutritional Management contributes to improvement in minimal hepatic encephalopathy and quality of life in patients with liver cirrhosis; a preliminary, prospective open-label study. Hepatol Res. 2013; 43(5):452-458.
60. Shibayama A, Nakajima H, Tokuue H. Muscle function and nutritional assessment in chronic liver disease. Jpn J Nutr Assessment 1994; 11: 383–6.
61. Suzuki K, Kato A, Onodera K, et al. Quality of life in patients with liver cirrhosis: effect of oral administration with branched-chain amino acid granules. Kan Tan Sui (Japan) 1999; 38: 817–21.
62. Naohiro Kawamura, Hiroshi Nakajima, Shinichi Takashi Administration of granulated BCAAS and quality of life The Third Department of Internal Medicine, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan Hepatology Research 30S (2004) S42–S45.